Table 4.

Prevalence of the autoantibodies in non-cirrhosis, compensated cirrhosis, and decompensated cirrhosis chronic hepatitis B groups n (%)

	Non-cirrhosis (n = 119)		Compensate cirrhosis (n = 85)		Decompensated cirrhosis (n = 121)
	Pos.	P value	Pos.	P value	Pos.	P value
ANA	39 (32.8)	0.006	16 (18.8)	0.027	21 (17.4)	0.787
SMA	1 (0.8)	0.393	3 (3.5)	0.131	6 (5.0)	0.882
AMA-M2	9 (7.6)	0.410	4 (4.7)	0.971	9 (7.4)	0.427
Anti-BPO	4 (3.4)	0.010	11 (12.9)	0.248	8 (6.6)	0.122
Anti-Sp100	2 (1.7)	1.000	2 (2.4)	0.694	4 (3.3)	1.000
Anti-PML	10 (8.4)	0.293	11 (12.9)	0.311	15 (12.4)	0.908
Anti-gp210	16 (13.4)	0.540	9 (10.6)	0.960	16 (13.2)	0.569
Anti-LKM-1	1 (0.8)	1.000	1 (1.2)	0.496	0 (0.0)	0.413
Anti-LC-1	3 (2.5)	1.000	3 (3.5)	1.000	4 (3.3)	1.000
Anti-SLA/LP	2 (1.7)	0.702	3 (3.5)	1.000	2 (1.7)	0.688
Anti-Ro52	33 (27.7)	0.629	21 (24.7)	0.628	37 (30.6)	0.356

P < 0.05, non-cirrhosis vs compensated cirrhosis, non-cirrhosis vs decompensated cirrhosis, and compensated vs decompensated cirrhosis, respectively. ANA: Anti-nuclear antibodies; AMA: Anti-mitochondrial antibodies; SMA: Smooth-muscle antibodies; anti-PML: Anti-promyelocytic leukemia protein; anti-LKM-1: Anti-liver kidney microsome type 1; anti-LC-1: Anti-liver cytosolic antigen type 1; anti-SLA/LP: Anti-soluble liver antigen/liver pancreas; IFA: Indirect immunofluorescence assay; LIA: Line immunoassay.